These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
77 related articles for article (PubMed ID: 9150695)
1. Results of somatostatin receptor scintigraphy do not predict pituitary tumor volume- and hormone-response to ocreotide therapy and do not correlate with tumor histology. Plöckinger U; Bäder M; Hopfenmüller W; Saeger W; Quabbe HJ Eur J Endocrinol; 1997 Apr; 136(4):369-76. PubMed ID: 9150695 [TBL] [Abstract][Full Text] [Related]
2. Combined visual and quantitative assessment of somatostatin receptor scintigraphy for staging and restaging of neuroendocrine tumors. Ueki Y; Otsuka H; Otani T; Kasai R; Otomi Y; Ikemitsu D; Azane S; Kunikane Y; Bando T; Matsuda N; Okada Y; Takayama T; Harada M Jpn J Radiol; 2024 May; 42(5):519-535. PubMed ID: 38345724 [TBL] [Abstract][Full Text] [Related]
3. Developing an optimal follow-up strategy based on the natural history of nonfunctioning pituitary adenomas. Kim JH; Dho YS; Kim YH; Lee JH; Lee JH; Hong AR; Shin CS J Neurosurg; 2019 Aug; 131(2):500-506. PubMed ID: 30215565 [TBL] [Abstract][Full Text] [Related]
4. Acromegaly caused by growth hormone-releasing hormone-producing tumors: long-term observational studies in three patients. Biermasz NR; Smit JW; Pereira AM; Frölich M; Romijn JA; Roelfsema F Pituitary; 2007; 10(3):237-49. PubMed ID: 17541749 [TBL] [Abstract][Full Text] [Related]
5. Pituitary apoplexy in endocrinologically silent adenoma during somatostatin analog administration for pancreatic neuroendocrine tumor: A case report. Shiraishi K; Akai T; Tomita T; Hayashi R; Minamisaka T; Kuroda S Neuropathology; 2024 Jun; 44(3):247-251. PubMed ID: 38099404 [TBL] [Abstract][Full Text] [Related]
6. The effect of preoperative short-term octreotide treatment to surgery in thyrotropin-secreting pituitary adenomas: a retrospective cohort study. Zhao R; Fan K; Wan W BMC Endocr Disord; 2023 Aug; 23(1):176. PubMed ID: 37587420 [TBL] [Abstract][Full Text] [Related]
7. Growth hormone increase by luteinizing hormone-releasing hormone reflects gonadotroph-related characteristics in acromegaly. Mitsui Y; Mukai K; Otsuki M; Oshino S; Saitoh Y; Kohara M; Morii E; Fukuhara A; Shimomura I Pituitary; 2024 Jun; ():. PubMed ID: 38954291 [TBL] [Abstract][Full Text] [Related]
8. Connexin 36 Mediated Intercellular Endoplasmic Reticulum Stress Transmission Induces SSTA Resistance in Growth Hormone Pituitary Adenoma. Wang Z; Lei Z; Wang Q; Jiang Q; Zhang Z; Liu X; Xing B; Li S; Guo X; Liu Y; Li X; Qi Y; Shu K; Zhang H; Huang Y; Lei T Int J Biol Sci; 2024; 20(2):801-817. PubMed ID: 38169563 [TBL] [Abstract][Full Text] [Related]
9. Pharmacological Treatment of Non-Functioning Pituitary Adenomas. Vargas-Ortega G; Gonzalez-Virla B; Romero-Gameros CA Arch Med Res; 2023 Dec; 54(8):102917. PubMed ID: 37996269 [TBL] [Abstract][Full Text] [Related]
10. FSH-producing pituitary neuroendocrine tumor as a cause of ovarian hyperstimulation syndrome. Kitamura T; Nanba K; Doi K; Kishimoto N; Abiko K; Kuwahara R; Moriyoshi K; Inoshita N; Tagami T Endocrinol Diabetes Metab Case Rep; 2024 Jan; 2024(1):. PubMed ID: 38421932 [TBL] [Abstract][Full Text] [Related]
11. Unravelling pituitary tumours in medically treated patients with acromegaly: the impact of systematic MRI reassessment. Atai S; Knudtzon Andersen M; Wiedmann M; Dahlberg D; Øystese KAB; Bollerslev J; Ringstad G; Heck A Acta Radiol; 2024 Jul; 65(7):753-758. PubMed ID: 38659302 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis. Del Corso LM; Mesa Junior CO; Andrade VFC; Fidalski SZK; Boguszewski CL Pituitary; 2024 Aug; ():. PubMed ID: 39088137 [TBL] [Abstract][Full Text] [Related]